HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $70.
HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $70.